The Medical Letter on Drugs and Therapeutics
Guanfacine Extended-Release (Intuniv) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An extended-release oral formulation of guanfacine hydrochloride (Intuniv – Shire), a selective alpha2A-adrenergic agonist, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old.

BACKGROUND — An immediate-release formulation of guanfacine (Tenex, and others) is marketed for treatment of hypertension. The alpha2-agonists guanfacine and clonidine (Catapres, and others) have been used off-label for years for treatment of ADHD, either alone or concurrently with stimulants such as methylphenidate or amphetamine, particularly in children with tics. Some Medical Letter consultants have used low doses of guanfacine concurrently with low doses of a stimulant to decrease the side effects of both drugs.

An extended-release formulation of clonidine (Kapvay – Shionogi) has also been approved by the FDA ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Guanfacine Extended-Release (Intuniv) for ADHD
Article code: 1349b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian